Sifr Capital

Sifr

Arabic for zero — the foundation of all computation.

We build companies from first principles.
We lead capital into them.
We do both because neither works alone.

$2B Team exits

$500K – $5M Check size

Series A+ Entry stage

Lead & Co-Lead Round position

Board Seat Every deal

Platform

Two integrated arms.

Arm I

Company Creation
and Incubation

We spin technologies out of universities and labs, de-risk the early science in our own facilities, and build from first principles. Our team embeds at every company as operators — not advisors.

Development roadmap and regulatory pathway
PK/PD, biomarker strategy, preclinical architecture
IP licensing, patent strategy, cap table design
Active roles: CSO, CMO, Board

Arm II

SPV-Based
Investments

We back select external opportunities at Series A and beyond through targeted SPVs. We co-invest our own capital alongside the family office on every deal and hold a board seat for governance.

Series A onward, technically validated only
$500K to $5M per deal
Co-investment alongside the family office
Board seat negotiated on every investment
Target exit horizon of 12 to 18 months

Team

Managing Partners.

Physician-scientist, operator, and inventor. MD with advanced training in clinical neuroscience and neurosurgical research at Johns Hopkins and Mayo Clinic, focused on neurotech, epilepsy, and brain-computer interfaces. Created an epilepsy monitoring device and led Scientific Affairs at Abbott across the entire IVDR portfolio, 200+ assays and $10B in revenue. Former roles at Siemens Healthineers, Johnson and Johnson, and Abbott. Angel investor and board member.

Karim ReFaey

Managing Partner and Co-Founder

Seasoned biotech operator and startup specialist with deep expertise across pharma and diagnostics. Secured $145M in financing, led a $140M acquisition with 280% value increase in 20 months, and grew IO product revenue from $70M to $105M. Founder, commercial strategist, and innovation catalyst across all stages of company development.

Vassili Kotlov

Managing Partner and Co-Founder

Verticals

Where we focus.

Healthcare and
Life Sciences

Drugs Devices Diagnostics Neurotech Longevity Research tools

Deep
Technology

AI Quantum Synthetic biology

Planetary
Health

Defense Aerospace biotech Energy Critical minerals Agriculture Environmental services

Portfolio

Built and backed.

Incubated

PlasticMind AI-driven precision dosing platform for personalized treatment in mental health and neurotherapeutics

Investments

Neuropsychiatry

Neurotech

Syndicate

A seat at
the table.

Direct access to our deals and a genuine working role in the companies we back. Deal by deal, no blind pool. Participation is based on expertise and qualifications, not capital.

Direct deal access

Deal-by-deal participation through targeted SPVs. No commitment to a fund.

Board and advisory roles

Opportunity to step into board seats and advisory positions within portfolio companies.

Clinical strategy

Help founders navigate reimbursement, trial design, and clinical positioning from the start.

Aligned economics

You invest on the same terms as the Sifr team and the family office on every deal.

Contact

Get in
touch.

For investors, physicians, entrepreneurs, and operators, and founders. All inquiries reviewed in confidence. We respond within five business days.